Martin Nutraceuticals Inc. (MNCL) cites a recent Canadian press article on Prexige, a member of the same drug class as Vioxx gaining Health Canada approval.
Prexige is also a Cox-2 inhibitor which has been brought to market as a treatment for new acute and chronic pain due to osteoarthritis of the knee in adults. This Cox-2 inhibitor is from the same class of drugs that were recently pulled from the market worldwide after studies showed people on the drug were almost double the risk of heart attack and stroke than non-users of these drugs, namely – Vioxx, Celebrex and Bextra.
An expert on Cox-2 inhibitors warned that all the drugs should be used with caution. “Patients at risk of heart disease should avoid all selective all selective Cox-2 inhibitors including Prexige, based on current evidence,” stated Dr. Garret FitzGerald, a cardiologist and pharmacologist at the University of Pennsylvania.
Dr. Tony Martin, Director of Research and Development for Martin Nutraceuticals, stated, “People are suffering from many forms of arthritis and because of this suffering; drugs which are not safe are being fast tracked into the marketplace. We at Martin Nutraceuticals, however offer an effective solution to these sufferers in the form of Arthrizyme, a product that is 100% natural and 100% safe. This is why Martin Nutraceuticals is becoming a valued name in helping all forms of joint pain.”